Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Abroad (travel likely)RecruitingPHASE2
Conditions
Cystic Fibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Kansas Medical Center, Kansas City, Kansas, United States
Matthias Salathe, M.D. (Sub-investigator)Andreas Schmid, M.D. (Sub-investigator)
Study leads
Charles Bengtson, MD, MSc
Principal Investigator
University of Kansas Medical Center